A retrospective study of 731 Chines CRC patients found that 48.3% (14/29) of cases with HER2 mutation were MSI-H, while no cases with HER2 amplification had MSI-H [26], such findings were also presented in our study, and the incidence of MSI-H in HER2 mutated cases was 32.7%. This evidence concerns the gene ERBB2 and colorectal carcinoma.